Tatva Chintan Pharma Chem Ltd Share Price

Chemicals - Speciality - Medium / SmallNSE
₹1,799.00
+55.80+3.20% (1D)
As on 5 Oct 2026 at 23:19
As of 5 Oct 2026 at 23:19, Tatva Chintan Pharma Chem Ltd is trading at ₹1,799.00, with a market cap of ₹4.19 thousand crore. At a P/E of 92.28 and a dividend yield of 0.11%, it is a small-cap stock in the Chemicals sector.

TATVA Price Chart

Market Cap
₹4.19K Cr
PE Ratio
92.28
ROCE
6.37%

Tatva Chintan Pharma Chem Ltd Performance

Tatva Chintan Pharma Chem Ltd Fundamentals

Market Cap₹4.19K Cr
ROE5.15%
P/E Ratio (TTM)92.28
EPS (TTM)₹19.40
P/B Ratio5.52
Dividend Yield0.11%
Industry P/E88.55
Book Value₹324.14
Debt to Equity0.16
Face Value₹10

Tatva Chintan Pharma Chem Ltd Shareholding Pattern

Promoter72%
Foreign Institutions3.9%
Mutual Funds2.8%
Domestic Institutions0.3%
Public20.9%

Tatva Chintan Pharma Chem Ltd Financial Statements

0100200300400500₹379FY24-3.24%₹366FY25+35.45%₹496FY26

*All values are in INR Crore

Tatva Chintan Pharma Chem Ltd Peer Comparison

StocksLTP(₹)Market Cap(Cr)
SRF Ltd
₹2,455.00
-31.20(-1.25%)
72,772.3
Linde India Ltd
₹6,029.20
-218.30(-3.49%)
51,419.6
Godrej Industries Ltd
₹1,039.10
19.50(+1.91%)
35,002.2
Himadri Speciality Chemical Ltd
₹659.80
-5.35(-0.80%)
33,291.8
Deepak Nitrite Ltd
₹1,497.35
4.55(+0.30%)
20,422.8

About Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem Limited was formerly incorporated as 'Tatva Chintan Pharma Chem Private Limited' on 12 June 1996. The status of the Company converted from Private Limited into a Public Limited Company from 27 January 2021 and the name of Company changed from 'Tatva Chintan Pharma Chem Private Limited' to 'Tatva Chintan Pharma Chem Limited'. The Company is an integrated specialty chemicals manufacturer with three decades of experience in complex and application-led chemistry. It is primarily engaged in manufacturing, distribution and selling of specialty chemicals i.e., Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts and Solutions (ESS), Pharmaceutical and Agrochemical Intermediates and Other Specialty Chemicals (PASC). These products cater to diverse industries such as pharmaceuticals, agrochemicals, automotive, electronics, resins and polymers, flavours and fragrances, personal care and disinfectants, oil field and energy storage. The Company operate through two world class manufacturing facilities located at Dahej and Ankleshwar in Gujarat both of which are strategically located closer to the Hazira Port. These units provide cost and logistics advantage through a seamless export and import operations. The Company have a dedicated Department of Scientific and Industrial Research (DSIR) approved R&D centre at its Vadodara facility where qualified and experienced in-house R&D team focus on development of new products and improvement in current manufacturing processes. The Company is having modern systems and analytical development laboratory with state-of-the-art instrumentation. In 2004, the Company received licence from the FDA, Gujarat at its Ankleshwar manufacturing plant. In 2007, the Company commenced Ankleshwar manufacturing facility and increased the expansion of manufacturing capacity. In 2011, the Company started commercial manufacturing of Structure Directing Agents (SDA). In 2015, the Company was accredited Appreciation Certificate for the Ankleshwar Plant from the Office of the Chief Commission of Central Excise, Customs & Service Tax, Vadodara Zone for its contribution to revenue and voluntary compliance with tax laws. The Company achieved revenue of nearly Rs 1 bn. The Company established a warehousing plant in The Netherlands. Tatva Chintan USA Inc. was incorporated as a wholly owned Subsidiary of TCPCL. In 2016, the Company was accorded the status of a two-star export house for the Ankleshwar plant from the Directorate General of Foreign Trade (DGFT), Ministry of Commerce and Industry (MoCI), Government of India (GoI). In 2017, manufacturing plant was established in Dahej, Gujarat. Tatva Chintan Europe BV, was incorporated as wholly owned Subsidiary of the Company in year 2019. In FY 2019-20, the Company's Ankleshwar unit was converted to a zero liquid effluent discharge facility. The products proved efficiency to ensure lower by-products and waste generation in chemical processes. Additionally, the Company participated in the Together for Sustainability' initiatives whereby sustainability sourcing practices of chemical suppliers, like ecological and social aspects were assessed. Under this initiative, the Company involved Ecovadis to audit sustainability practices and performance, the results of which were above the industry average. This created a robust initiative and focused on retaining key customers who consider sustainability an important parameter to do business. In 2021, the manufacturing capacity at Dahej facility in Gujarat increased giving rise to aggregate installed reactor manufacturing capacity of the Company from 160 KL and 10 Assembly Lines to 280 KL and 17 Assembly Lines respectively. The Company launched its Initial Public Offer cum Offer for Sale of 46,16,804 Equity Shares by raising funds from public aggregating to Rs 500 Crore, comprising a Fresh Issue of 20,77,562 Equity Shares aggregating to Rs 225 Crore and an Offer for Sale of 25,39,242 Equity Shares aggregating to Rs 275 Crore in July, 2021. The Company commenced commercial production from the newly expanded facility at Dahej SEZ. With this, the installed reactor capacity increased to 500 KL from 294 KL and assembly lines increased from 27 to 39 in 2023-24. It has started production at Distillation Plant in 2026.

Parent Organisation—
Founded1996
Managing Director—
NSE SymbolTATVA

Tatva Chintan Pharma Chem Ltd Resistance and Support levels

R31,852.47R21,809.64R11,783.19S11,697.54S21,671.09S31,628.271,799.00

Tatva Chintan Pharma Chem Ltd Technicals

Current Price
₹1,799.00 ₹55.80 (+3.20%)
Bearish
0
Bullish
12
  • 20 Day4.4%
  • 50 Day9.1%
  • 100 Day16.9%
  • 200 Day27.8%

Tatva Chintan Pharma Chem Ltd Latest News

View More
23 SEPT 2026 | Wednesday
Tatva Chintan restricts trading for insiders ahead of September 2026 results
08 SEPT 2026 | Tuesday
CRISIL upgrades Tatva Chintan Pharma Chem's ratings, reflecting substantial credit facilities
27 AUG 2026 | Thursday
Tatva Chintan Pharma Chem closes shareholder books September 12-25 for AGM
21 JUL 2026 | Tuesday
Tatva Chintan Pharma Chem commences construction of greenfield unit at Dahej
20 JUL 2026 | Monday
Tatva Chintan Pharma Chem Ltd leads gainers in 'B' group
20 JUL 2026 | Monday
Tatva Chintan Pharma rallies after Q1 PAT jumps more than two-fold
11 JUL 2026 | Saturday
Tatva Chintan Pharma Chem to hold board meeting
18 MAY 2026 | Monday
Board of Tatva Chintan Pharma Chem recommends final dividend
06 MAY 2026 | Wednesday
Tatva Chintan Pharma Chem to conduct board meeting

2026

Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Tatva Chintan Pharma Chem Ltd is ₹1,799.00 as of 5 Oct 2026 at 23:19.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now